Hormoontherapie voor prostaatkanker: gevolgen voor de botgezondheid

The treatment of prostate cancer with androgen deprivation therapy (ADT) causes a decrease in bone density as a side effect. For prescribers of this treatment, knowledge of the prevention of osteoporosis and fracture risk is important, as well as knowledge about the indication for follow-up testing or indication for additional lifestyle measures and therapy. In this article we discuss the relationship of ADT with osteoporosis and fracture risk based on the literature and give recommendations based on the Dutch prostate cancer guideline and the recently published Dutch guideline on osteoporosis and fracture prevention.